BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.

2019年12月23日 · 公司的主要候选产品crx-100，是一种不需要肿瘤内给药，通过静脉给药用于治疗实体瘤的联合疗法。 联合免疫疗法包括免疫细胞，保护溶瘤病毒在到达肿瘤之前不被免疫系统消除。

2024年12月4日 · The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may prevent relapse. It targets epithelial ovarian cancer, melanoma, non-small cell lung cancer, triple negative breast, gastric cancer, hepatocellular carcinoma ...

2020年4月28日 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100...

CRX100 is a combined immunotherapy currently in Phase 1b/2a clinical trial. This technology demonstrated excellent preclinical potency against a broad range of tumor types and has been producing exciting data in the clinic. This is the first in human trial using adoptive NK-T cells combined with an oncolytic vaccinia virus (CRX100).

BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.

CRX-100是由斯坦福大学研发的一种细胞疗法和溶瘤病毒，是一种细胞死亡刺激剂和细胞毒性T淋巴细胞刺激剂。 目前该药物最高研发阶段为临床一期，用于治疗非小细胞肺癌、肝细胞癌、骨肉瘤、黑色素瘤、结直肠癌、卵巢上皮癌、三阴性乳腺癌、实体瘤和胃癌。

2020年4月28日 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers.

CRX-100 is being developed by BioEclipse Therapeutis for the treatment of patients with advanced solid tumors. (Sourced from:

2015年12月25日 · Based on preclinical animal model results, combining CIK cells and virus has the potential to become a viable treatment option. CRX100 migrates to the tumor site, targets tumors cells and delivers the cancer-destroying virus while healthy cells are not targeted. Q: How do I enroll in this trial?